HK1041645B - 生物可降解聚合物包封的5-羥色胺受體拮抗劑及其製備方法 - Google Patents

生物可降解聚合物包封的5-羥色胺受體拮抗劑及其製備方法

Info

Publication number
HK1041645B
HK1041645B HK02103401.5A HK02103401A HK1041645B HK 1041645 B HK1041645 B HK 1041645B HK 02103401 A HK02103401 A HK 02103401A HK 1041645 B HK1041645 B HK 1041645B
Authority
HK
Hong Kong
Prior art keywords
preparing
same
receptor antagonist
biodegradable polymer
serotonin receptor
Prior art date
Application number
HK02103401.5A
Other languages
English (en)
Other versions
HK1041645A1 (en
Inventor
R‧S‧科恩
S‧J‧漢雷
S‧J‧科米斯基
Original Assignee
Aventisub Ii Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventisub Ii Inc filed Critical Aventisub Ii Inc
Publication of HK1041645A1 publication Critical patent/HK1041645A1/xx
Publication of HK1041645B publication Critical patent/HK1041645B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
HK02103401.5A 1998-12-16 2002-05-04 生物可降解聚合物包封的5-羥色胺受體拮抗劑及其製備方法 HK1041645B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (2)

Publication Number Publication Date
HK1041645A1 HK1041645A1 (en) 2002-07-19
HK1041645B true HK1041645B (zh) 2005-07-29

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103401.5A HK1041645B (zh) 1998-12-16 2002-05-04 生物可降解聚合物包封的5-羥色胺受體拮抗劑及其製備方法

Country Status (35)

Country Link
EP (1) EP1140026B1 (zh)
JP (1) JP4759141B2 (zh)
KR (1) KR100707710B1 (zh)
CN (1) CN1195497C (zh)
AP (1) AP1769A (zh)
AR (1) AR021652A1 (zh)
AT (1) ATE303795T1 (zh)
AU (1) AU770673B2 (zh)
BG (1) BG65500B1 (zh)
BR (1) BR9916276A (zh)
CA (1) CA2355077C (zh)
CR (1) CR6424A (zh)
CZ (1) CZ301947B6 (zh)
DE (1) DE69927177T2 (zh)
DK (1) DK1140026T3 (zh)
EA (1) EA004502B1 (zh)
EE (1) EE200100314A (zh)
ES (1) ES2245128T3 (zh)
HK (1) HK1041645B (zh)
HR (1) HRP20010446A2 (zh)
HU (1) HU226586B1 (zh)
ID (1) ID28909A (zh)
IL (2) IL143761A0 (zh)
ME (2) MEP19408A (zh)
NO (1) NO20012981L (zh)
NZ (1) NZ511962A (zh)
OA (1) OA11728A (zh)
PL (1) PL196822B1 (zh)
RS (1) RS50123B (zh)
SK (1) SK285812B6 (zh)
TR (1) TR200101759T2 (zh)
TW (1) TWI221418B (zh)
UA (1) UA73101C2 (zh)
WO (1) WO2000035423A1 (zh)
ZA (1) ZA200104899B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
ATE369122T1 (de) 2001-05-23 2007-08-15 Hexal Ag Verfahren zur herstellung von implantaten mittels lösungsmittelfreier herstellung eines homogenisats
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
WO2006032202A1 (en) * 2004-09-21 2006-03-30 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102159193B (zh) * 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
EP4084607A4 (en) * 2019-12-31 2023-06-21 Wanka Tanka Ltd. TIME-RELEASE PLASTIC FORMULATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (zh) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
ES2185615T3 (es) * 1990-05-16 2003-05-01 Southern Res Inst Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
RS50123B (sr) 2009-03-25
BG65500B1 (bg) 2008-10-31
ES2245128T3 (es) 2005-12-16
TWI221418B (en) 2004-10-01
NZ511962A (en) 2003-06-30
MEP19408A (en) 2010-06-10
AR021652A1 (es) 2002-07-31
HK1041645A1 (en) 2002-07-19
DK1140026T3 (da) 2006-01-02
CZ301947B6 (cs) 2010-08-11
EE200100314A (et) 2002-08-15
AU1742500A (en) 2000-07-03
HUP0105048A3 (en) 2002-09-30
BG105591A (en) 2002-01-31
DE69927177D1 (de) 2005-10-13
PL348233A1 (en) 2002-05-20
OA11728A (en) 2005-02-01
ID28909A (id) 2001-07-12
NO20012981L (no) 2001-07-27
KR20010082359A (ko) 2001-08-29
KR100707710B1 (ko) 2007-04-18
EA004502B1 (ru) 2004-04-29
NO20012981D0 (no) 2001-06-15
SK8282001A3 (en) 2001-11-06
AP2001002198A0 (en) 2001-09-30
YU41401A (sh) 2003-12-31
EA200100551A1 (ru) 2001-10-22
AU770673B2 (en) 2004-02-26
JP4759141B2 (ja) 2011-08-31
CN1330536A (zh) 2002-01-09
UA73101C2 (en) 2005-06-15
CA2355077C (en) 2009-05-26
WO2000035423A1 (en) 2000-06-22
ZA200104899B (en) 2002-09-16
TR200101759T2 (tr) 2001-12-21
IL143761A0 (en) 2002-04-21
JP2002532408A (ja) 2002-10-02
ATE303795T1 (de) 2005-09-15
BR9916276A (pt) 2001-09-04
AP1769A (en) 2007-08-22
IL143761A (en) 2006-08-01
DE69927177T2 (de) 2006-06-08
WO2000035423A9 (en) 2002-08-22
CA2355077A1 (en) 2000-06-22
PL196822B1 (pl) 2008-02-29
CZ20012157A3 (cs) 2001-09-12
EP1140026A1 (en) 2001-10-10
CR6424A (es) 2004-02-26
HRP20010446A2 (en) 2002-06-30
EP1140026B1 (en) 2005-09-07
HU226586B1 (en) 2009-04-28
ME00066B (me) 2010-06-10
SK285812B6 (sk) 2007-08-02

Similar Documents

Publication Publication Date Title
AP2001002198A0 (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
EP1100506A4 (en) INTEGRIN RECEPTOR ANTAGONISTS
HUP0104914A3 (en) Galenicformulations fast disintegrating the mouth and method for preparing same
EP1229910A4 (en) integrin
EP1194151A4 (en) ANTAGONISTS OF THE INTEGRIN RECEPTORS
SG80041A1 (en) Muscarinic receptor antagonists
PL342881A1 (en) Vitronectin receptor antagonists
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
GB9826881D0 (en) Coupled polymers and process for preparing the same
IL127304A0 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
IL127417A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
SG83788A1 (en) Method for preparing polymer
IL141163A0 (en) Vitronectin receptor antagonists
PL343426A1 (en) Method for preparing sulfanyl-type endothelin receptor antagonists
GB9811283D0 (en) Vironectin receptor antagonists
GB9807940D0 (en) Alpha-1a adrenergic receptor antagonists
GB9923910D0 (en) Prolactin receptor
GB9603373D0 (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111122